The Vanguard Group 13D and 13G filings for Relay Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-07-29 2:22 pm Sale | 2025-06-30 | 13G | Relay Therapeutics, Inc. RLAY | The Vanguard Group | 9,379,851 5.470% | -2,725,569 (-22.52%) | Filing |
| 2025-04-30 11:12 am Purchase | 2025-03-31 | 13G | Relay Therapeutics, Inc. RLAY | The Vanguard Group | 12,105,420 7.140% | 1,455,033 (+13.66%) | Filing |
| 2024-02-13 5:13 pm Purchase | 2023-12-29 | 13G | Relay Therapeutics, Inc. RLAY | The Vanguard Group | 10,650,387 8.640% | 266,169 (+2.56%) | Filing |
| 2023-02-09 11:30 am Purchase | 2022-12-30 | 13G | Relay Therapeutics, Inc. RLAY | The Vanguard Group | 10,384,218 8.590% | 4,185,776 (+67.53%) | Filing |
| 2022-02-10 08:32 am Purchase | 2021-12-31 | 13G | Relay Therapeutics, Inc. RLAY | The Vanguard Group | 6,198,442 5.740% | 6,198,442 (New Position) | Filing |